FOXO TECHNOLOGIES INC.

FOXO Technologies Inc. (NYSE American: FOXO) is an insurtech company operating at the intersection of epigenetic biomarker science and life insurance underwriting, with the goal of using molecular data to assess policyholder longevity risk. The company filed a Form S-1 registration statement in September 2020, and subsequently completed a business combination in 2022 with CF Acquisition Corp VIII, a blank-check company sponsored by an affiliate of Cantor Fitzgerald. FOXO trades on NYSE American and operates in the financial technology and life insurance sector. The company's shares have faced significant pressure in the post-merger period common among de-SPAC transactions. For complete filing history, transaction documents, and data on FOXO and thousands of other SPAC-related companies, sign up for full access on SpacDesk.